<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6137">
  <stage>Registered</stage>
  <submitdate>19/10/2016</submitdate>
  <approvaldate>19/10/2016</approvaldate>
  <nctid>NCT02940691</nctid>
  <trial_identification>
    <studytitle>Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs</studytitle>
    <scientifictitle>A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use</scientifictitle>
    <utrn />
    <trialacronym>DARLO-C</trialacronym>
    <secondaryid>VHCRP1510</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Grazoprevir/elbasvir

Experimental: Grazoprevir/elbasvir - Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.


Treatment: drugs: Grazoprevir/elbasvir
Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The proportion of patients with undetectable HCV RNA at 12 weeks post end of treatment (SVR12) following interferon-free and ribavirin-free DAA therapy with grazoprevir/elbasvir among PWID with recent injecting drug use and chronic HCV genotype 1 or 4.</outcome>
      <timepoint>12 weeks post treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the rate of HCV reinfection up to three years following interferon-free and ribavirin-free DAA therapy with grazoprevir/elbasvir.</outcome>
      <timepoint>3 year post treatment commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Participants have voluntarily signed the informed consent form.

          -  Be =18 years of age on day of signing informed consent form.

          -  Have HCV infection as documented by detectable HCV RNA.

          -  Have HCV genotype 1 or 4 infection.

          -  Recent injecting drug use (previous 6 months).

          -  HIV-1 infected subjects enrolled in the study must meet the following criteria:

               -  Have HIV infection documented by any licensed rapid HIV test or HIV enzyme or
                  chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry
                  (Baseline) and confirmed by a licensed Western blot or a second antibody test by
                  a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 p24 antigen,
                  or plasma HIV-1 RNA viral load

               -  Be naive to treatment with any antiretroviral therapy (ART) (and have no plans to
                  initiate ART treatment while participating in this study and through at least
                  Follow-up Week 4 OR be on HIV Antiretroviral Therapy (ART) for at least 4 weeks
                  prior to study entry using an ART regimen that is allowable with the intended DAA
                  regimen as determined by the current PI and the Liverpool drug interaction
                  website (http://www.hiv-druginteractions.org/) or current prescribing guidelines
                  for grazoprevir/elbasvir.

          -  Negative pregnancy test at screening and baseline (females of childbearing potential
             only).

          -  All fertile males and females must be using effective contraception during treatment
             and during 14 days after treatment end.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Is taking or plans to take any prohibited medications as per DAA Product Information
             or herbal supplements, including but not limited to St. John's Wort (Hypericum
             perforatum) within 2 weeks of Baseline.

          -  Is currently using or intends to use barbiturates.

          -  Is a female and is pregnant or breast-feeding, or expecting to conceive or donate eggs
             from Baseline and continue throughout treatment, and after the last dose of study
             medication (as per the regimen requirements), or longer if dictated by local
             regulations.

          -  Has any condition or pre-study laboratory abnormality, ECG abnormality or history of
             any illness, which, in the opinion of the investigator, might confound the results of
             the study or pose additional risk in administering the study drugs to the subject.

          -  Had a life-threatening SAE during the screening period.

          -  Has exclusionary laboratory values as listed below:

               -  Haemoglobin &lt; 9.5 g/dL for both males and females

               -  Platelets &lt; 50 x 103 /ÂµL

               -  Serum albumin &lt; 3.0 g/dL

          -  Patients with Child Pugh-B or C decompensated cirrhosis

          -  Previous HCV treatment-experience.

          -  Ongoing severe psychiatric disease as judged by the treating physician.

          -  Frequent injecting drug use that is judged by the treating physician to compromise
             treatment safety.

          -  Inability or unwillingness to provide informed consent or abide by the requirements of
             the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Kirketon Road Centre - Darlinghurst</hospital>
    <hospital>St Vincent's Hospital - Darlinghurst</hospital>
    <hospital>The Langton Centre - Darlinghurst</hospital>
    <hospital>Nepean Hospital - Kingswood</hospital>
    <hospital>Drug and Alcohol Clinical Services (Hunter) - Newcastle</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2751 - Kingswood</postcode>
    <postcode>2300 - Newcastle</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Kirby Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is a phase IV, open-label, single arm, multicentre study whose aim is to assess
      whether interferon-free and ribavirin-free Direct Acting Antiviral (DAA) Hepatitis C Virus
      (HCV) therapy with grazoprevir/elbasvir, will be feasible for the treatment of People who
      inject drugs (PWID) with recent injecting drug use and chronic HCV genotype 1 or 4 infection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02940691</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Greg Dore, MBBS</name>
      <address>Kirby Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Pip Marks</name>
      <address />
      <phone>+61 2 9385 0886</phone>
      <fax />
      <email>pmarks@kirby.unsw.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>